DKSH has formed a strategic partnership with NanoCellect Biomedical, a manufacturer of unique cartridge-based cell sorters and image-guided cell analyzers and sorters. DKSH will leverage its expertise and global experience to enhance NanoCellect’s business opportunities in six new markets in Southeast Asia.
Singapore, September 3, 2024 – DKSH Business Unit Technology has formed a partnership with NanoCellect Biomedical, a manufacturer of unique cartridge-based and image-guided cell analyzers and sorters. DKSH will provide sales, marketing, application support, and after-sales services in Singapore, Malaysia, Vietnam, Philippines, Indonesia, and Thailand.
NanoCellect specializes in designing and manufacturing advanced cell analysis and sorting solutions. Their product range includes cutting-edge cell sorters equipped with innovative cartridge-based technology for gentle sorting of various fragile cell types, including stem cells. In addition to their core sorting instruments, NanoCellect offers a range of essential add-ons that enhance laboratory workflows. These include single-cell dispensing modules, which enable precise cell isolation for downstream applications such as single-cell genomics, cell line development, cell therapies and basic research. NanoCellect’s cartridge consumables play a critical role in ensuring the efficiency and accuracy of their sorting systems, making them indispensable tools for research and clinical laboratories seeking reliable solutions for high viability gentle cell sorting.
Paul DiGregorio, Vice President Commercial at NanoCellect, expressed: “NanoCellect is excited to collaborate with DKSH. With their established track record, extensive experience, and leading position as the top distributor in the region, they are the ideal partner to facilitate our expansion in the APAC region. Their proficiency in sales, marketing, application, and after-sales support of flow cytometry products ensure the successful adoption of our innovative solutions in the life science industry. Together with DKSH, we are introducing technologies benefiting researchers in academic and biopharma settings.”
Marco Farina, Senior Director of Business Development and Center of Excellence at DKSH, remarked: “We are enthusiastic about partnering with NanoCellect. Integrating their complementary products into our current life science portfolio aims to enrich our offerings and deliver comprehensive solutions to our customers in the field of genomics, antibody discovery, cell line development, and Crispr gene editing. Together with NanoCellect, we anticipate driving growth and delivering outstanding value to our customers.”
About NanoCellect
NanoCellect is committed to empowering every scientist to make discoveries one cell at a time. They develop and deliver microfluidic-based solutions that are affordable, compact, and easy to use. By ensuring the high cell viability required to advance cell-based research, NanoCellect’s expanding portfolio of instruments and consumables enables biomedical scientists to analyze and sort cells required for drug discovery, single cell-omics, cloning, antibody discovery, and basic research. www.nanocellect.com
About DKSH
DKSH’s purpose is to enrich people’s lives. For almost 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 29,040 specialists, generating net sales of CHF 11.1 billion in 2023. DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health, and over-the-counter products as well as medical devices. With around 8,140 specialists, the Business Unit generated net sales of CHF 5.6 billion in 2023. www.dksh.com/hec